[{"id":"9afa710d-568f-4738-a48f-bfb574489fff","acronym":"HFB-200603-01","url":"https://clinicaltrials.gov/study/NCT05789069","created_at":"2023-03-29T14:03:20.087Z","updated_at":"2025-02-25T15:13:24.022Z","phase":"Phase 1","brief_title":"A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05789069 - HFB-200603-01","lead_sponsor":"HiFiBiO Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • HFB200603"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-13"}]